Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 39; no. 6; p. 460
• Main Authors: Gong, B F, Tan, Y H, Liao, A J, Li, J, Mao, Y Y, Lu, N, Ding, Y, Jiang, E L, Gong, T J, Jia, Z L, Sun, Y, Li, B Z, Liu, S C, Du, J, Huang, W R, Wei, H, Wang, J X
• Format: Journal Article
• Language: Chinese
• Published: China 14.06.2018
• Subjects: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute - therapy; Prognosis; Retrospective Studies; Salvage Therapy; Leukemia, myeloid, acute; Recurrence; Gene, KIT; Prognosis; Mutation
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2018.06.004

To evaluate the impact of KIT D816 mutation on the salvage therapy in relapsed acute myeloid leukemia (AML) with t(8;21) translocation. The characteristics of the first relapsed AML with t(8;21) translocation from 10 hospitals were retrospectively collected, complete remission (CR(2)) rate after one course salvage chemotherapy and the relationship between KIT mutation and CR(2) rate was analyzed. 68 cases were enrolled in this study, and 30 cases (44.1%) achieved CR(2). All patients received KIT mutation detection, and KIT D816 mutation was identified in 26 cases. The KIT D816 positive group had significantly lower CR(2) compared with non-KIT D816 group (23.1% 57.1%, (2)=7.559, =0.006), and patients with longer CR(1) duration achieved significantly higher CR(2) than those with CR(1) duration less than 12 months (74.1% 31.9%, (2)=9.192, =0.002). KIT D816 mutation was tightly related to shorter CR(1) duration. No significant difference of 2 years post relapse survival was observed between KIT D816 mutation and